An in-depth study is presented to better understand how data reduction via averaging impacts retention alignment and the subsequent chemometric analysis of data obtained using gas chromatography (GC). We specifically study the use of signal averaging to reduce GC data, retention time alignment to correct run-to-run retention shifting, and principal component analysis (PCA) to classify chromatographic separations of diesel samples by sample class. Diesel samples were selected because they provide sufficient complexity to study the impact of data reduction on the data analysis strategies. The data reduction process reduces the data sampling ratio, S(R), which is defined as the number of data points across a given chromatographic peak width (i.e., the four standard deviation peak width). Ultimately, sufficient data reduction causes the chromatographic resolution to decrease, however with minimal loss of chemical information via the PCA. Using PCA, the degree of class separation (DCS) is used as a quantitative metric. Three "Paths" of analysis (denoted A-C) are compared to each other in the context of a "benchmark" method to study the impact of the data sampling ratio on preserving chemical information, which is defined by the DCS quantitative metric. The benchmark method is simply aligning data and applying PCA, without data reduction. Path A applies data alignment to collected data, then data reduction, and finally PCA. Path B applies data reduction to collected data, and then data alignment, and finally PCA. The optimized path, namely Path C, is created from Paths A and B, whereby collected data are initially reduced to fewer data points (smaller S(R)), then aligned, and then further reduced to even fewer points and finally analyzed with PCA to provide the DCS metric. Overall, following Path C, one can successfully and efficiently classify chromatographic data by reducing to a S(R) of ∼15 before alignment, and then reducing down to S(R) of ∼2 before performing PCA. Indeed, following Path C, results from an average of 15 different column length-with-temperature ramp rate combinations spanning a broad range of separation conditions resulted in only a ∼15% loss in classification capability (via PCA) when the loss in chromatographic resolution was ∼36%.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.chroma.2011.10.031 | DOI Listing |
Alzheimers Dement
December 2024
School of Pharmacy, Chapman University, Irvine, CA, USA.
Background: Although novel treatments for Alzheimer's disease (AD) have begun to show modest therapeutic effects, agents that target hallmark AD pathology and offer neuroprotection are desired. Erythropoietin (EPO) is a glycoprotein hormone with neuroprotective effects but is faced with challenges including limited brain uptake and increased hematopoietic side effects with long-term dosing. Therefore, EPO has been modified and bound to a chimeric transferrin receptor monoclonal antibody (cTfRMAb); the latter shuttles EPO past the blood-brain barrier (BBB) into brain parenchyma and reduces its plasma exposure and potential for side effects.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Edith Cowan University, Perth, Western Australia, Australia.
Background: Accumulation of amyloid beta 42 (Aβ42) senile plaques is the most critical event leading to Alzheimer's disease (AD). Currently approved drugs for AD have not been able to effectively modify the disease. This has caused increasing research interests in health beneficial nutritious plant foods as viable alternative therapy to prevent or manage AD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Washington University School of Medicine, St. Louis, MO, USA.
Background: The well-accepted statistical efficacy inference approach for Alzheimer's disease (AD) clinical trials compares the absolute difference in change from baseline at the last study visit using MMRM (henceforth referred to as MMRM-Last-Visit). Recent AD clinical trials have shown that treatment effects may be manifested prior to 18 months. The objective is to evaluate models estimating an overall treatment effect across all post-baseline visits that may characterize disease modifying effects in contemporary early AD clinical trials.
View Article and Find Full Text PDFBackground: While a number of recent anti-amyloid antibodies demonstrated a robust reduction of amyloid biomarkers in clinical trials, the impact on functional improvement is much more variable. We hypothesize that this larger variability is driven by comedications, common genotype variants and underlying tau pathology.
Method: In a previously calibrated computational neuroscience model of ADAS-Cog, we implemented the effect of soluble amyloid monomers and oligomers on glutamate and nicotinic AChR neurotransmission and the effect of intracellular tau oligomers on voltage-gated Na and K+ channels and synaptic density.
Alzheimers Dement
December 2024
STEM Neurology & Neuropsychological0 Research Group Egypt (SNRGE), Port Said, Port Said, Egypt.
Background: Donepezil, an acetylcholinesterase inhibitor (AChEI), is an FDA-approved drug to treat these neurodegenerative diseases, e.g., Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!